Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease

Thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly (TAFRO) syndrome is a heterogeneous entity manifesting with a constellation of symptoms described above that can occur in the context of idiopathic multicentric Castleman disease (iMCD) as well as infectious diseases, malignancies, and rheumatologic disorders. So, iMCD‐TAFRO is an aggressive subtype of iMCD with TAFRO syndrome and often hyper‐vascularized lymph nodes. Since we proposed diagnostic criteria of iMCD‐TAFRO in 2016, we have accumulated new insights on the disorder and additional cases have been reported worldwide. In this systematic review and cohort analysis, we established and validated a definition for iMCD‐TAFRO. First, we searched PubMed and Japan Medical Abstracts Society databases using the keyword “TAFRO” to extract cases. Patients with possible systemic autoimmune diseases and hematologic malignancies were excluded. Our search identified 54 cases from 50 articles. We classified cases into three categories: (1) iMCD‐TAFRO (TAFRO syndrome with lymph node histopathology consistent with iMCD), (2) possible iMCD‐TAFRO (TAFRO syndrome with no lymph node biopsy performed and no other co‐morbidities), and (3) TAFRO without iMCD or other co‐morbidities (TAFRO syndrome with lymph node histopathology not consistent with iMCD or other comorbidities). Based on the findings, we propose an international definition requiring four clinical criteria (thrombocytopenia, anasarca, fever/hyperinflammatory status, organomegaly), renal dysfunction or characteristic bone marrow findings, and lymph node features consistent with iMCD. The definition was validated with an external cohort (the ACCELERATE Natural History Registry). The present international definition will facilitate a more precise and comprehensive approach to the diagnosis of iMCD‐TAFRO.

[1]  S. Rose-John,et al.  Interleukin-6: obstacles to targeting a complex cytokine in critical illness , 2021, The Lancet Respiratory Medicine.

[2]  Luke Y. C. Chen,et al.  COVID-19 cytokine storm syndrome: a threshold concept , 2021, The Lancet Microbe.

[3]  E. Jaffe,et al.  ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder , 2020, Cell reports. Medicine.

[4]  É. Oksenhendler,et al.  Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease , 2020, American journal of hematology.

[5]  F. Otsuka,et al.  Disseminated Mycobacterium genavense infection mimicking TAFRO syndrome. , 2020, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[6]  O. Abe,et al.  Computed tomography findings of early-stage TAFRO syndrome and associated adrenal abnormalities , 2020, European Radiology.

[7]  K. Ohashi,et al.  The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome , 2020, Kidney international reports.

[8]  Amber Dance.  What is a cytokine storm? , 2020 .

[9]  A. Dispenzieri,et al.  Overview of Castleman Disease. , 2020, Blood.

[10]  F. Otsuka,et al.  Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6‐year retrospective study , 2020, Internal medicine journal.

[11]  Y. Ishigaki,et al.  2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome , 2019, International Journal of Hematology.

[12]  D. Fajgenbaum.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. , 2018, Blood.

[13]  S. Bozkurt,et al.  TAFRO Syndrome: A Case Report from Turkey and Review of the Literature , 2018, International journal of hematology-oncology and stem cell research.

[14]  T. Zhu,et al.  TAFRO Syndrome – A Specific Subtype of Castleman's Disease in China , 2018, Chinese medical journal.

[15]  S. Paydaş.  Tafro syndrome: Critical review for clinicians and pathologists. , 2018, Critical reviews in oncology/hematology.

[16]  A. Ortiz,et al.  Neuro-ophthalmological findings in TAFRO syndrome in a patient from South America, a variant of multicentric Castleman’s disease , 2018, International Ophthalmology.

[17]  K. Notohara,et al.  TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review , 2018, Modern rheumatology.

[18]  K. Ohashi,et al.  Renal histology in a patient with TAFRO syndrome: a case report. , 2018, Human pathology.

[19]  Hiroki Sato,et al.  Characterization of patients with systemic lupus erythematosus who meet the diagnostic criteria for TAFRO syndrome , 2018, Lupus.

[20]  S. Humbert,et al.  A comparison of TAFRO syndrome between Japanese and non-Japanese cases: a case report and literature review , 2018, Annals of Hematology.

[21]  K. Ohashi,et al.  TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report , 2018, CEN Case Reports.

[22]  N. Siritanaratkul,et al.  High proportion of TAFRO syndrome in Thai adult Castleman’s disease patients: a 10-year experience , 2018, Annals of Hematology.

[23]  K. Sakashita,et al.  TAFRO syndrome: current perspectives , 2018, Journal of blood medicine.

[24]  K. Shiozawa,et al.  Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan , 2018, Modern rheumatology.

[25]  T. Yoshino,et al.  A possible new morphological variant of mantle cell lymphoma with plasma-cell type Castleman disease-like features. , 2017, Pathology, research and practice.

[26]  D. Fajgenbaum,et al.  TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature , 2017, Front. Med..

[27]  R. Ando,et al.  Successful treatment by tocilizumab without steroid in a very severe case of TAFRO syndrome , 2017, CEN Case Reports.

[28]  N. Hamerschlak,et al.  A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids , 2017, Medicine.

[29]  T. Sekine,et al.  Diffuse Large B-cell Lymphoma during Corticosteroid Therapy for TAFRO Syndrome , 2016, Internal medicine.

[30]  E. Jaffe,et al.  Multicentric Castleman disease: Where are we now? , 2016, Seminars in diagnostic pathology.

[31]  M. Kojima,et al.  Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version , 2016, International Journal of Hematology.

[32]  L. Pantanowitz,et al.  TAFRO syndrome: An atypical variant of KSHV‐negative multicentric Castleman disease , 2016, American journal of hematology.

[33]  T. Yoshino,et al.  Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV‐8‐negative multicentric Castleman disease , 2016, American journal of hematology.

[34]  N. Komatsu,et al.  [Autoimmune hemolytic anemia in a patient with TAFRO syndrome]. , 2015, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[35]  A. Allegra,et al.  Castleman-Kojima disease (TAFRO syndrome) in a Caucasian patient: A rare case report and review of the literature. , 2015, Blood cells, molecules & diseases.

[36]  M. Kojima,et al.  Castleman-Kojima disease (TAFRO syndrome) : a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June, 2012 , 2013, Journal of clinical and experimental hematopathology : JCEH.

[37]  Tomomi Sato,et al.  Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? , 2013, Journal of clinical and experimental hematopathology : JCEH.

[38]  H. Shibuya,et al.  [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly]. , 2010, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[39]  R. Bridges,et al.  VERSION , 1922, Greece and Rome.

[40]  Takako Morita,et al.  [Systemic lupus erythematosus with marked eosinophilia and clinical features mimicking TAFRO syndrome]. , 2018, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[41]  Masahiro Ito,et al.  TAFRO syndrome with primary Sjogren's syndrome. , 2016, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology.

[42]  K. Takata,et al.  Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. , 2013, Journal of clinical and experimental hematopathology : JCEH.